The clinical and economic benefits of school-based quadrivalent HPV vaccination in Singapore

Tay, Sun Kuie; Hsu, Tun-Ying; Shcheprov, A. V.; Walia, Anuj; Kulkarni, Amit

doi:10.1002/ijgo.12126

Cited by 8 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ICER was one‐tenth of the ICER when one switched from quadrivalent to nonavalent HPV vaccination. In this respect, previous cost‐effectiveness analysis from Singapore has also reported an advantage of quadrivalent vaccine over bivalent vaccine …”

Section: Discussionmentioning

confidence: 94%

“…The long‐term impact of mass HPV vaccination is enormous. As yet, there is no school‐based HPV vaccination in Singapore despite previous studies showing that school‐based HPV vaccination is cost‐effective for both quadrivalent and bivalent HPV vaccines . Nonavalent HPV vaccine extends the protection of quadrivalent vaccine to HPV 31/33/45/52/58 infection and related CIN and cervical cancer.…”

Section: Discussionmentioning

confidence: 99%

“…In this respect, previous cost-effectiveness analysis from Singapore has also reported an advantage of quadrivalent vaccine over bivalent vaccine. 28,29 Evidence from real-world experience of mass HPV vaccination in the previous decade has demonstrated that prophylactic HPV vaccination should form an important part of cervical cancer prevention strategy and a very high vaccine uptake rate of 80-90% can be achieved in school-based HPV vaccination programmes. [30][31][32][33] The long-term impact of mass HPV vaccination is enormous.…”

Section: Discussionmentioning

confidence: 99%

“…As yet, there is no school-based HPV vaccination in Singapore despite previous studies showing that school-based HPV vaccination is cost-effective for both quadrivalent and bivalent HPV vaccines. 28,29,34 Nonavalent HPV vaccine extends the protection of quadrivalent vaccine to HPV 31/33/45/52/58 infection and related CIN and cervical cancer. It also adds to the bivalent vaccine, the protection of HPV 6/11 infection and related CIN1 and genital warts in women and men.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Clinical and economic impact of school‐based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis

Tay

Hsu

Pavelyev³

et al. 2018

BJOG

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical and economic impact of school‐based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis

Tay

Hsu

Pavelyev³

et al. 2018

BJOG

View full text Add to dashboard Cite

show abstract

“…The 4vHPV vaccine, a highly successful prophylactic vaccine, [65][66][67] was licensed more than 8 y ahead of the 9vHPV vaccine. Therefore, the initial one or 2 doses (or even the full course of the 3-dose immunization) of the 4vHPV vaccine may have been administered before the availability of the 9vHPV vaccine.…”

Section: Use Of the 9vhpv Vaccine In Subjects Previously Vaccinated Wmentioning

confidence: 99%

Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine

Zhang

Xia

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Human papillomavirus is considered the causative factor for cervical cancer, which accounts for approximately 5% of the global cancer burden and more than 600,000 new cases annually that are attributable to HPV infection worldwide. The first-generation prophylactic HPV vaccines, Gardasil® and Cervarix®, were licensed approximately a decade ago. Both vaccines contain the most prevalent high-risk types, HPV16 and 18, which are associated with 70% of cervical cancer. To further increase the type coverage, 5 additional oncogenic HPV types (31, 33, 45, 52 and 58) were added to the existing Gardasil-4 to develop a 9-valent HPV vaccine (9vHPV), Gardasil 9®, increasing the potential level of protection from ∼70% to ∼90%. The efficacy of the vaccine lies primarily in its ability to elicit type-specific and neutralizing antibodies to fend off the viral infection. Therefore, type-specific and neutralizing murine monoclonal antibodies (mAbs) were used to quantitate the antigenicity of the individual vaccine antigens and to measure the antibody levels in the serum samples from vaccinees in a type- and epitope-specific manner in a competitive immunoassay. Assays for 9vHPV are extended from the proven platform used for 4vHPV by developing and adding new mAbs against the additional types. In Phase III clinical trials, comparable safety profile and immunogenicity against the original 4 types were demonstrated for the 9vHPV vaccine, and these were comparable to the 4vHPV vaccine. The efficacy of the 9vHPV vaccine was established in trials with young women. Immunobridging for younger boys and girls was performed, and the results showed higher immunogenicity in the younger age group. In a subsequent clinical trial, the 2-dose regimen of the 9vHPV vaccine used among girls and boys aged 9-14 y showed non-inferior immunogenicity to the regular 3-dose regimen for young women (aged 16-26 years). Overall, the clinical data and cost-effectiveness analysis for the 9vHPV vaccine support its widespread use to maximize the impact of this important, life-saving vaccine.

show abstract

The cost-effectiveness of bivalent, quadrivalent, and nine-valent HPV vaccination in Asia: a systematic review

Zhu

Tian

Dong

et al. 2022

Arch Gynecol Obstet

View full text Add to dashboard Cite

The clinical and economic benefits of school-based quadrivalent HPV vaccination in Singapore

Abstract: School-based quadrivalent HPV vaccination offered clinical and economic benefits, and is cost-effective in Singapore.

Cited by 8 publications

References 18 publications

Clinical and economic impact of school‐based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis

Clinical and economic impact of school‐based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis

Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine

The cost-effectiveness of bivalent, quadrivalent, and nine-valent HPV vaccination in Asia: a systematic review

Contact Info

Product

Resources

About